In his weekly clinical update Dr. Griffin discusses the annual economic burden of respiratory syncytial virus in adults in the US, recombinant or standard-dose influenza vaccine in adults under 65 years of age, maternal vaccine effectiveness against influenza-associated hospitalizations and emergency department visits in iInfants, influenza positive tests reported to CDC by US clinical laboratories, update on COVID-19, risk of severe maternal morbidity associated with SARS-CoV-2 infection during pregnancy, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation, long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study, and risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• RSV economic burden, US (J Inf Dis)
• Recombinant or standard dose influenza vaccine (NEJM)
• Maternal vaccine effectiveness against influenza in Infants (JAMA Ped)
• Weekly influenza surveillance report (MMWR)
• COVID data tracker (hospital admissions, national trend)
• Risk of severe maternal morbidity associated with SARS-CoV-2 infection (J Inf Dis)
• COVID-19 rapid antigen tests with nasal and throat swab specimens (JAMA Net Open)
• Optimal timing of nirmatrelvir/ritonavir (Nat Comm)
• Long-term outcomes following hospital admission for COVID-19 vs influenza (Lancet)
• Contribute to our MicrobeTV fundraiser at PWB
• Letters read on TWiV 1072
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]